CN102639134A - 使用基质金属蛋白酶-2抑制剂治疗动脉瘤样扩张、血管壁薄弱、特别是腹主动脉瘤和胸主动脉瘤的方法 - Google Patents

使用基质金属蛋白酶-2抑制剂治疗动脉瘤样扩张、血管壁薄弱、特别是腹主动脉瘤和胸主动脉瘤的方法 Download PDF

Info

Publication number
CN102639134A
CN102639134A CN2010800545319A CN201080054531A CN102639134A CN 102639134 A CN102639134 A CN 102639134A CN 2010800545319 A CN2010800545319 A CN 2010800545319A CN 201080054531 A CN201080054531 A CN 201080054531A CN 102639134 A CN102639134 A CN 102639134A
Authority
CN
China
Prior art keywords
vessel wall
compound
inhibitors
treatment
angiotensin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2010800545319A
Other languages
English (en)
Chinese (zh)
Inventor
A.J.J.伍德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Symphony Evolution Inc
Original Assignee
Symphony Evolution Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Symphony Evolution Inc filed Critical Symphony Evolution Inc
Publication of CN102639134A publication Critical patent/CN102639134A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN2010800545319A 2009-10-01 2010-09-30 使用基质金属蛋白酶-2抑制剂治疗动脉瘤样扩张、血管壁薄弱、特别是腹主动脉瘤和胸主动脉瘤的方法 Pending CN102639134A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24784309P 2009-10-01 2009-10-01
US61/247,843 2009-10-01
PCT/US2010/050907 WO2011041545A1 (en) 2009-10-01 2010-09-30 Methods of treating aneurysmal dilatation, blood vessel wall weakness and specifically abdominal aortic and thoracic aneurysm using matrix metalloprotease-2 inhibitors

Publications (1)

Publication Number Publication Date
CN102639134A true CN102639134A (zh) 2012-08-15

Family

ID=43034492

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2010800545319A Pending CN102639134A (zh) 2009-10-01 2010-09-30 使用基质金属蛋白酶-2抑制剂治疗动脉瘤样扩张、血管壁薄弱、特别是腹主动脉瘤和胸主动脉瘤的方法

Country Status (6)

Country Link
US (2) US20120270884A1 (enExample)
EP (1) EP2482817A1 (enExample)
JP (1) JP2013506684A (enExample)
CN (1) CN102639134A (enExample)
CA (1) CA2774389A1 (enExample)
WO (1) WO2011041545A1 (enExample)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107417629A (zh) * 2017-08-09 2017-12-01 苏州楚凯药业有限公司 动脉瘤抑制剂xl784的制备方法
CN108947850A (zh) * 2018-07-23 2018-12-07 蚌埠中实化学技术有限公司 一种3,4,5-三氟苯胺的制备方法
CN111500721A (zh) * 2020-04-20 2020-08-07 青岛大学附属医院 Tace在腹主动脉瘤腔内修复术后内漏诊断中的应用
CN112569219A (zh) * 2019-09-30 2021-03-30 中国科学院上海药物研究所 用于治疗动脉相关疾病的药物及其用途

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013506684A (ja) * 2009-10-01 2013-02-28 シンフォニー エボリューション， インコーポレイテッド マトリックスメタロプロテアーゼ−２阻害剤を用いた、動脈瘤性拡張、血管壁脆弱性、特に腹部大動脈瘤および胸部動脈瘤を治療する方法
WO2013059302A1 (en) * 2011-10-17 2013-04-25 Nationwide Children's Hospital, Inc. Products and methods for aortic abdominal aneurysm
US20150297629A1 (en) * 2012-07-27 2015-10-22 Isis Pharmaceuticals, Inc. Modulation of renin-angiotensin system (ras) related diseases by angiotensinogen
WO2014028334A1 (en) * 2012-08-11 2014-02-20 Symphony Evolution, Inc. Selective mmp inhibitors
EP2916133B1 (en) 2012-10-30 2019-10-02 Tohoku University Method for testing for cardiovascular disease with cyclophilin a
JP2018530325A (ja) 2015-10-08 2018-10-18 アイオーニス ファーマシューティカルズ， インコーポレーテッドＩｏｎｉｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． アンジオテンシノーゲンの発現を調節するための化合物及び方法
US11376248B2 (en) * 2017-06-30 2022-07-05 Georgia State University Research Foundation, Inc. Treatment of aneurysms
US11273148B2 (en) 2017-09-01 2022-03-15 The Johns Hopkins University Targeted epigenetic therapy for inherited aortic aneurysm condition
LT4136092T (lt) 2020-11-18 2024-09-25 Ionis Pharmaceuticals, Inc. Junginiai ir būdai, skirti angiotenzinogeno raiškos moduliavimui

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003106381A2 (en) * 2002-06-12 2003-12-24 Exelixis, Inc. Human adam-10 inhibitors
US20040215172A1 (en) * 2003-04-25 2004-10-28 Jack Chu In situ blood vessel and aneurysm treatment
EP1516598A1 (en) * 2003-09-19 2005-03-23 Medtronic Vascular, Inc. Device for delivering of therapeutics to treat aneurysms
EP1600181A2 (en) * 2004-05-27 2005-11-30 Medtronic Vascular, Inc. Methods and compounds for treatment of aneurysmal tissue
WO2007050793A2 (en) * 2005-10-25 2007-05-03 The Johns Hopkins University Methods and compositions for the treatment of marfan syndrome and associated disorders
US20080207552A1 (en) * 2002-03-29 2008-08-28 Anges Mg, Inc. Decoy compositions for treating and preventing brain diseases and disorders

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU723836B2 (en) 1996-08-29 2000-09-07 Regents Of The University Of California, The Kuz, a novel family of metalloproteases
US5922546A (en) 1997-08-25 1999-07-13 Smithkline Beecham Corporation Human disintegrin metalloprotease KUZ gene
KR20010033473A (ko) * 1997-12-23 2001-04-25 로즈 암스트롱, 크리스틴 에이. 트러트웨인 Ａｃｅ 저해제-ｍｍｐ 저해제의 병용 제제
AUPP584198A0 (en) * 1998-09-14 1998-10-08 Fujisawa Pharmaceutical Co., Ltd. New use
JP2009502179A (ja) * 2005-07-29 2009-01-29 インペリアル イノベーションズ リミテッド 化合物
JP2013506684A (ja) * 2009-10-01 2013-02-28 シンフォニー エボリューション， インコーポレイテッド マトリックスメタロプロテアーゼ−２阻害剤を用いた、動脈瘤性拡張、血管壁脆弱性、特に腹部大動脈瘤および胸部動脈瘤を治療する方法

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080207552A1 (en) * 2002-03-29 2008-08-28 Anges Mg, Inc. Decoy compositions for treating and preventing brain diseases and disorders
WO2003106381A2 (en) * 2002-06-12 2003-12-24 Exelixis, Inc. Human adam-10 inhibitors
US20040215172A1 (en) * 2003-04-25 2004-10-28 Jack Chu In situ blood vessel and aneurysm treatment
EP1516598A1 (en) * 2003-09-19 2005-03-23 Medtronic Vascular, Inc. Device for delivering of therapeutics to treat aneurysms
EP1600181A2 (en) * 2004-05-27 2005-11-30 Medtronic Vascular, Inc. Methods and compounds for treatment of aneurysmal tissue
WO2007050793A2 (en) * 2005-10-25 2007-05-03 The Johns Hopkins University Methods and compositions for the treatment of marfan syndrome and associated disorders

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
李春平: "基质金属蛋白酶及其组织抑制剂在腹动脉瘤发病中的作用", 《现代临床普通外科》 *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107417629A (zh) * 2017-08-09 2017-12-01 苏州楚凯药业有限公司 动脉瘤抑制剂xl784的制备方法
CN107417629B (zh) * 2017-08-09 2020-02-07 苏州楚凯药业有限公司 动脉瘤抑制剂xl784的制备方法
CN108947850A (zh) * 2018-07-23 2018-12-07 蚌埠中实化学技术有限公司 一种3,4,5-三氟苯胺的制备方法
CN108947850B (zh) * 2018-07-23 2021-05-18 蚌埠中实化学技术有限公司 一种3,4,5-三氟苯胺的制备方法
CN112569219A (zh) * 2019-09-30 2021-03-30 中国科学院上海药物研究所 用于治疗动脉相关疾病的药物及其用途
CN112569219B (zh) * 2019-09-30 2023-05-02 中国科学院上海药物研究所 用于治疗动脉相关疾病的药物及其用途
CN111500721A (zh) * 2020-04-20 2020-08-07 青岛大学附属医院 Tace在腹主动脉瘤腔内修复术后内漏诊断中的应用

Also Published As

Publication number Publication date
WO2011041545A1 (en) 2011-04-07
EP2482817A1 (en) 2012-08-08
CA2774389A1 (en) 2011-04-07
US20120270884A1 (en) 2012-10-25
JP2013506684A (ja) 2013-02-28
US20110082114A1 (en) 2011-04-07

Similar Documents

Publication Publication Date Title
CN102639134A (zh) 使用基质金属蛋白酶-2抑制剂治疗动脉瘤样扩张、血管壁薄弱、特别是腹主动脉瘤和胸主动脉瘤的方法
JP4718172B2 (ja) ヒトａｄａｍ−１０インヒビター
EP1378247B1 (en) Visual function disorder improving agents
KR101663436B1 (ko) N-치환된 벤즈아미드 및 이의 사용 방법
KR20190043158A (ko) 융합된 비시클릭 sGC 자극제
JP2003522733A (ja) Ｘａ因子の阻害剤としてのアルケニルおよびアルキニル化合物
CZ20012637A3 (cs) 2,3,4,5-tetrahydro-1H[1,4]benzodiazepin-3-hydroxamové kyseliny jako inhibitory metaloproteináz mezibuněčné hmoty
JP2022544031A (ja) リシルオキシダーゼのジフルオロハロアリルアミンスルホン誘導体阻害剤、調製方法、及びそれらの使用
CN102325768B (zh) 治疗疼痛和其他疾病的化合物和方法
US20200062803A1 (en) Azaindoline compounds as granzyme b inhibitors
EA016594B1 (ru) Производные 1-(аминоалкоксиарилсульфонил)индола в качестве 5-нтлигандов
CN109836378B (zh) 一类鞘磷脂合酶抑制剂、其制备方法及其应用
CN107531598A (zh) 用于治疗纤维化和纤维化相关病症的组合物
JP2001517623A (ja) トロンビン阻害薬
EP1197487B1 (en) Benzimidazole compounds and drugs containing the same
JP2001524522A (ja) トロンビン阻害剤
WO2009052200A2 (en) Human adam-10 inhibitors
WO2018130207A1 (zh) 4,4-二苯基哌啶类化合物或其可药用盐、药物组合物及用途
CN109180672A (zh) 亚氨基噻二嗪二氧化物衍生物及其用途
NZ260889A (enExample)
MC2418A1 (fr) Procédé de préparation d'un acide (-) - (3R)-3-méthyl-4-[4-[4- (4-pyridyl) pipérazine-1-yl] phénoxy]butyrique et d'une composition pharmaceutique le contenant

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20120815